SCHEMBL6166973

SCHEMBL6166973

Cc1nn(-c2ccccc2)c2c1C(=O)CC(C)(C)C2N

nearest known ligand 0.73

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
CCNA2 P20248 18/20 0.73
CDK2 P24941 18/20 0.73
CCNO P22674 3/20 0.52
CCNE1 P24864 3/20 0.52
CCNA1 P78396 3/20 0.52
CDK5 Q00535 4/20 0.50
CDK5R1 Q15078 4/20 0.50
MEN1 O00255 1/20 0.47
ALDH1A1 P00352 1/20 0.47
KMT2A Q03164 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
OPRM1 P35372 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6166305 0.73 OPRM1 (0.76) MEN1ALDH1A1KMT2ASMN1; SMN2OPRM1
SCHEMBL6164565 0.68 CCNA2 (1.00) CCNA2CDK2CCNOCCNE1CCNA1
SCHEMBL6164739 0.68 CCNA2 (1.00) CCNA2CDK2CCNOCCNE1CCNA1
SCHEMBL6165208 0.68 CCNA2 (1.00) CCNA2CDK2CCNOCCNE1CCNA1
SCHEMBL6164744 0.67 CCNA2 (0.72) CCNA2CDK2CCNOCCNE1CCNA1
SCHEMBL6163398 0.67 CCNA2 (1.00) CCNA2CDK2CCNOCCNE1CCNA1
SCHEMBL6163976 0.66 CCNA2 (0.67) CCNA2CDK2CCNOCCNE1CCNA1
SCHEMBL6772430 0.66 CCNA2 (0.44) CCNA2CDK2CCNOCCNE1CCNA1
SCHEMBL6162529 0.65 OPRM1 (0.56) CCNA2CDK2MEN1ALDH1A1KMT2A
SCHEMBL6167870 0.65 ALDH1A1 (0.49) CCNA2CDK2MEN1ALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1177185-B1 4, 5, 6, 7-TETRAHYDROINDAZOLE DERIVATIVES AS ANTITUMOR AGENTS PHARMACIA ITALIA SPA (IT) 2005-04-20 EP disclosed
US-6716856-B1 CELL PROLIFERATIVE DISORDERS OR ALZHEIMER'S DISEASE; REDUCED TOXICITY; CDK/CYCLIN KINASE INHIBITORY ACTIVITY PHARMACIA & TUBJOHN SPA (IT) 2004-04-06 US disclosed